Alkaline ophthalmic suspensions
February 8, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2798053 Opthalmic solution Ophthalmic solution Method of treatment for glaucoma Polysiloxane hydrogels Water-insoluble hydrophilic copolymers Method of treating vascularization of the eye with Flurbiprofen Sustained release ophthalmic drug dosage Ophthalmic solutions Sustained release ophthalmic drug dosage InventorsAssigneeApplicationNo. 014512 filed on 02/08/1993US Classes:424/78.04, Ophthalmic preparation424/427, Ocular424/428, Bioerrodable, resorbable, or dissolving424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)514/912, OPHTHALMIC514/913, Glaucoma514/914InflammationExaminersPrimary: Page, Thurman K.Assistant: Azpuru, Carlos Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/74A61K 009/14 A61F 002/14 AbstractTopical ophthalmic medicament delivery system combining an aqueous ophthalmic gel suspension at a pH equal to or greater than 7.5 and an osmotic pressure of from 10 to about 400 mOsM containing a pharmaceutically effective amount of one or more ophthalmic medicaments of from about 0.05% to about 10% by weight, based on the total weight of the suspension, of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less then about 5% by weight of a cross-linking agent. The systems have a viscosity of from about 1,000 to about 30,000 centiposes prior to administration to the eye and remain a gel in the eye for a prolonged period of time allowing for the sustained release of one or medicaments such as amine containing antibiotics alone or in combination with cortiscosteroids.Other References
| |
